A new treatment option has entered the European market for one of the most challenging post-transplant complications.
The European Commission has granted conditional marketing authorisation to Rezurock (belumosudil) for treating chronic graft-versus-host disease (GVHD).
This decision follows a positive recommendation from the European Medicines Agency’s CHMP in January 2026.
What This Approval Means?
Rezurock is now approved in the EU for:
- Adults and children ≥12 years
- Minimum body weight: 40 kg
- Patients with limited or failed prior treatment options
This is not a full approval. It’s a conditional marketing authorisation, which means:
- Approval is based on existing clinical evidence
- A confirmatory randomised controlled trial is mandatory
- Continued approval depends on future data
Why Chronic GVHD Is So Difficult to Treat?
Graft-versus-host disease (GVHD) occurs after allogeneic stem cell transplantation.
What happens:
- Donor immune cells attack the patient’s body
- Leads to inflammation and fibrosis
- Multiple organs can be affected
The burden:
- Affects up to 50% of transplant patients
- Major cause of late mortality and morbidity
- Often becomes chronic and debilitating
For many patients: Treatment options run out quickly. Nearly 1 in 2 patients require third-line therapy, where choices have historically been limited.
The Drug: How Rezurock Works?
Rezurock (belumosudil) is a:
- Selective ROCK2 inhibitor (rho-associated coiled-coil kinase 2)
Why this matters:
ROCK2 plays a role in:
- Immune regulation
- Inflammation
- Fibrosis
By targeting this pathway, Rezurock aims to:
- Reduce immune overactivation
- Limit tissue damage
- Improve functional outcomes
The Data Behind the Decision
The approval is supported by multiple datasets, including the ROCKstar Phase II trial.
Key highlights:
- Overall Response Rate (ORR): 74%
- Statistically significant (p < 0.0001)
- Durable responses observed
- Patients had 2–5 prior lines of therapy
Safety profile:
Most common side effects:
- Fatigue (46%)
- Diarrhoea (35%)
- Nausea (35%)
- Dyspnoea (32%)
- Cough (30%)
- Upper respiratory infections (26%)
Overall: The treatment was generally well tolerated.
Global Footprint So Far
Rezurock is not new globally. It is already approved in:
- United States
- United Kingdom
- Canada
- China
Across markets:
- 20+ countries approved
- 20,000+ patients treated since 2021
This EU approval expands access significantly.
Orphan Drug Status: Why It Matters
Rezurock received orphan designation in 2019.
Following this approval:
- The EMA’s Committee for Orphan Medicinal Products confirmed continued designation
Benefits include:
- Regulatory incentives
- Market exclusivity
- Support for rare disease innovation
What Experts Are Saying?
Mohamad Mohty emphasized the unmet need:
“Chronic GVHD is serious and life-threatening… this approval offers a meaningful new option.”
From industry, Olivier Charmeil added:
“Nearly one in two patients need third-line treatment, yet options have remained limited.”
What Comes Next?
The story isn’t finished. Under conditional approval, Sanofi must:
- Conduct a confirmatory randomised controlled trial
- Validate long-term efficacy and safety
Meanwhile, ongoing studies are exploring:
- Use in younger paediatric populations (≥1 year)
- Other conditions like chronic lung allograft dysfunction
The Real Takeaway
This approval fills a critical gap—but with caveats.
What’s strong:
- High response rates in heavily pretreated patients
- Novel mechanism (ROCK2 inhibition)
- Real-world usage already established
What’s pending:
- Confirmatory Phase III data
- Long-term comparative effectiveness
Final Thoughts
For chronic GVHD patients who have exhausted options, Rezurock is not just another drug—it’s a lifeline with conditions attached. The opportunity is clear.
Now it comes down to one question: Can confirmatory data convert this conditional win into a full standard-of-care shift?